CN111372583B - 青蒿素衍生的三聚体和四聚体及其用途 - Google Patents

青蒿素衍生的三聚体和四聚体及其用途 Download PDF

Info

Publication number
CN111372583B
CN111372583B CN201880075374.6A CN201880075374A CN111372583B CN 111372583 B CN111372583 B CN 111372583B CN 201880075374 A CN201880075374 A CN 201880075374A CN 111372583 B CN111372583 B CN 111372583B
Authority
CN
China
Prior art keywords
compound
alkyl
artesunate
nhc
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880075374.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111372583A (zh
Inventor
赵鸣
周丽明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202410656901.XA priority Critical patent/CN118546165A/zh
Publication of CN111372583A publication Critical patent/CN111372583A/zh
Application granted granted Critical
Publication of CN111372583B publication Critical patent/CN111372583B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CN201880075374.6A 2017-11-21 2018-11-21 青蒿素衍生的三聚体和四聚体及其用途 Active CN111372583B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410656901.XA CN118546165A (zh) 2017-11-21 2018-11-21 青蒿素衍生的三聚体和四聚体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762588921P 2017-11-21 2017-11-21
US62/588,921 2017-11-21
PCT/US2018/062356 WO2019104247A1 (en) 2017-11-21 2018-11-21 Artemisinin-derived trimers and tetramers and their use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410656901.XA Division CN118546165A (zh) 2017-11-21 2018-11-21 青蒿素衍生的三聚体和四聚体及其用途

Publications (2)

Publication Number Publication Date
CN111372583A CN111372583A (zh) 2020-07-03
CN111372583B true CN111372583B (zh) 2024-06-14

Family

ID=66632152

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880075374.6A Active CN111372583B (zh) 2017-11-21 2018-11-21 青蒿素衍生的三聚体和四聚体及其用途
CN202410656901.XA Pending CN118546165A (zh) 2017-11-21 2018-11-21 青蒿素衍生的三聚体和四聚体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410656901.XA Pending CN118546165A (zh) 2017-11-21 2018-11-21 青蒿素衍生的三聚体和四聚体及其用途

Country Status (5)

Country Link
US (2) US11358970B2 (enExample)
EP (1) EP3713566A4 (enExample)
JP (1) JP7282294B2 (enExample)
CN (2) CN111372583B (enExample)
WO (1) WO2019104247A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111372583B (zh) * 2017-11-21 2024-06-14 赵鸣 青蒿素衍生的三聚体和四聚体及其用途
CA3131244A1 (en) * 2019-02-26 2020-09-03 Mahmoud A. Eisohly Selected artemisinin dimers for the treatment of lashmaniasis
CN113264946A (zh) * 2021-05-11 2021-08-17 中国人民解放军陆军军医大学第一附属医院 一种双氢青蒿素衍生物及其在制备治疗、预防脑血管病药物中的应用
CN115282145A (zh) * 2022-09-05 2022-11-04 中南大学湘雅二医院 青蒿琥酯在制备治疗青光眼的药物或制剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177978A1 (zh) * 2012-05-30 2013-12-05 北京凯正生物工程发展有限责任公司 青蒿琥酯聚乙二醇化衍生物、其药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100529600B1 (ko) 2003-01-23 2005-11-22 정만길 디옥소아테미시닌 유사체, 그의 제조방법 및 그를포함하는 항암제
EP2411003A4 (en) 2009-03-24 2012-10-17 Univ Singapore USE OF ARTEMISININE DERIVATIVES IN THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE BRONCHO-PNEUMOPATHY (COPD)
DK2424880T3 (en) * 2009-04-28 2016-10-24 Res Dev Foundation Immunoreactive Ehrlichia p120 / p140 epitopes, and uses thereof
WO2010135427A2 (en) * 2009-05-19 2010-11-25 The Johns Hopkins University Trioxane monomers and dimers
WO2011071981A2 (en) 2009-12-08 2011-06-16 The Johns Hopkins University Anti-cytomegalovirus activity of artemisinin-derived dimers
CN102153564B (zh) 2011-01-31 2013-07-24 中国科学院上海药物研究所 含氮原子的青蒿素二聚体、其制备方法及用途
EP3269371A1 (en) 2011-06-10 2018-01-17 Queen Mary University of London Artemisinin and its derivatives for use in the treatment of myocardial infarction or coronary heart disease
WO2014090306A1 (en) 2012-12-12 2014-06-19 Queen Mary & Westfield College, University Of London Artemisinin and its derivatives for use in the treatment of kidney disease
US9314460B1 (en) 2013-04-09 2016-04-19 Stc.Unm Method for cancer cell reprogramming
CN105078964A (zh) 2015-08-20 2015-11-25 桂林医学院附属医院 青蒿琥酯在制备治疗特发性肺纤维化药物中的应用
CN111372583B (zh) * 2017-11-21 2024-06-14 赵鸣 青蒿素衍生的三聚体和四聚体及其用途
CN109467565B (zh) 2018-08-16 2020-07-10 云白药征武科技(上海)有限公司 双氢青蒿素三聚体及其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177978A1 (zh) * 2012-05-30 2013-12-05 北京凯正生物工程发展有限责任公司 青蒿琥酯聚乙二醇化衍生物、其药物组合物及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers;Desmond Slade等;《Bioorganic & Medicinal Chemistry》;20091015;7952页右栏第2段，表2-4，图1 *
Desmond Slade等."Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.《Bioorganic & Medicinal Chemistry》.2009, *
Highly Potent Artemisinin-derived Dimers and Trimers: Synthesis and Evaluation of their Antimalaria, Antileukemia and Antiviral activities;Christoph Reiter等;《Bioorganic & Medicinal Chemistry》;20150825;摘要，表2 *

Also Published As

Publication number Publication date
JP7282294B2 (ja) 2023-05-29
WO2019104247A1 (en) 2019-05-31
EP3713566A1 (en) 2020-09-30
CN118546165A (zh) 2024-08-27
US20210079011A1 (en) 2021-03-18
EP3713566A4 (en) 2021-07-14
CN111372583A (zh) 2020-07-03
US12134624B2 (en) 2024-11-05
US20220275003A1 (en) 2022-09-01
JP2021504302A (ja) 2021-02-15
US11358970B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
CN111372583B (zh) 青蒿素衍生的三聚体和四聚体及其用途
US7799776B2 (en) Indoleamine 2,3-dioxygenase (IDO) inhibitors
AU2014262621B2 (en) STAT6 inhibitors
HUE031506T2 (en) Aldose reductase inhibitors and their use
US20110178050A1 (en) Use of cyclolignans for the treatment of a hyperactive immune system
JP2022031806A (ja) アルテスナート含有組成物
CN111662294A (zh) 一类具有降解Btk活性的化合物
CN109879933A (zh) 一类含磷酰基化合物及其应用
CN113024422B (zh) 丁苯酞开环化合物、药物化合物以及它们的制备方法、组合物和应用
US20180105550A1 (en) Cytidine derivative dimers and applications thereof
CN109796519B (zh) 一类甾体化合物及其应用
CN113603743B (zh) 一类具有联合治疗作用的cddo/川芎嗪醇杂合物及其制备方法和用途
CN113490669A (zh) 一类具有降解Btk活性的化合物
KR20150014910A (ko) 허혈-재관류계 질환의 치료 화합물
CN119233975A (zh) 新型化合物及其用于治疗自身免疫性疾病的用途
WO2019233366A1 (zh) 选择性a 2a受体拮抗剂
US20070249556A1 (en) Method of treating inflammation
CN115260107B (zh) 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用
US20070286906A1 (en) Dihydrobenzoquinone compounds
CN113637031A (zh) 一种结构新颖的二价铂类化合物及其用途
US20060110467A1 (en) Cancer chemotherapy
WO2025140361A1 (zh) 甘草次酸衍生物及其用途
JP2017081864A (ja) 抗腫瘍剤
WO2025252264A1 (zh) 用于治疗或预防呼吸道合胞病毒疾病的化合物
CN119053597A (zh) 乙型肝炎抗病毒剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant